The findings highlight the regional specificity of the association of WMHs with AD. 2 key findings →
Design: longitudinal study Participants: 717 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
In response to KKM treatment, 68 genes were found to be differentially expressed (19 up-regulated, 49 down-regulated) after adjusting for potentially confounded differences in sex, illness burden, and BMI. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Higher intake of omega-3 fatty acids (n-3 FAs) is associated with a reduced risk of Alzheimer's disease (AD) and milder forms of cognitive impairment (e.g. cognitive impairment no dementia [CIND]); however, findings from interventional trials are inconsistent. 4 key findings →
Design: meta-analysis Participants: 934 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The application of support vector machine classification (SVM) to combined information from magnetic resonance imaging (MRI) and [F18]fluorodeoxyglucose positron emission tomography (FDG-PET) has been shown to improve detection and differentiation of Alzheimer's disease dementia (AD) and frontotemporal lobar degeneration. 4 key findings →
Design: meta-analysis Participants: 21 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This longitudinal study examined whether insulin resistance among late middle-aged, cognitively healthy individuals was associated with 1) less gray matter in Alzheimer disease-sensitive brain regions and 2) worse cognitive performance. 4 key findings →
Design: longitudinal study Participants: 372 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
65/100
The heterogeneous patterns and severity of conditions produce distinctive cumulative effects for each individual.5 Multimorbidity is associated with many adverse consequences, including death, disability, institutionalization, greater use of healthcare resources, poorer quality of life, and higher rates of adverse effects of treatment or interventions.1 Comprehensive strategies for healthcare delivery that are not disease specific, as well as interventions that target geriatric syndromes common in older adults with multimorbidity, show promise for this population,5-9 although the best approaches to decision-making and clinical management of older adults with multimorbidity remain unclear. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
64/100
Treatment with sertraline in patients with dAD is not associated with greater improvement in cognition at week 24 than treatment with placebo. 2 key findings →
Participants: 67 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The neuropathologic examination is considered to provide the gold standard for Alzheimer disease (AD). 5 key findings →
Participants: 1,198 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
64/100
Recent studies suggest that delirium is associated with risk of dementia and also acceleration of decline in existing dementia. 5 key findings →
Participants: 232 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Twelve months' treatment with doxycycline or rifampin, alone or in combination, has no beneficial effects on cognition or function in AD. 5 key findings →
Design: randomized controlled trial Participants: 305 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The aim of this multicenter randomized controlled trial was to determine whether the incidence of dislocation one year after total hip arthroplasty is significantly lower in association with the use of a 36-mm femoral head articulation as compared with a 28-mm articulation. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
There are a substantial number of people with dementia worldwide and these numbers will continue to increase mainly in LMIC, producing a wide range of impacts. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
Prevalence of swallowing difficulties in patients with dementia ranged from 13 to 57%. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Of the participants, 342 (81.6%) had normal cognitive functioning, 58 (13.8%) had nonamnestic MCI, and 19 (4.5%) had amnestic MCI. 5 key findings →
Design: cohort study Participants: 419 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Measurements and main results Criterion validity and overall accuracy of the Czech version of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) were determined using serial daily delirium assessments with CAM-ICU by a junior physician compared with delirium diagnosis by delirium experts using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria that began the first day after stroke onset and continued for at least 7 days. 2 key findings →
Design: cohort study Participants: 129 Evidence: moderate
Full summary, score breakdown and related studies → Original source
SSD in older people may be a frequent and clinically important condition that falls on a continuum between no symptoms and full delirium. 3 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
A systematic review of the literature was conducted to examine the relationship between ethnic minority status and provision of end-of-life care for people with dementia. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
There is evidence that excessive stress exposure of the brain, mediated through the neurotoxic effects of cortisol and possibly neuroinflammation, causes damage to brain structure and function: the glucocorticoid cascade hypothesis. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
We performed a systematic review and meta-analysis of neural predictors of response to the most commonly used, evidence based treatments in clinical practice, namely pharmacological and psychological therapies. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
Existing drugs for Alzheimer's disease provide symptomatic benefit for up to 12 months, but there are no approved disease-modifying therapies. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source
This review shows that communication skills training in dementia care significantly improves the quality of life and wellbeing of people with dementia and increases positive interactions in various care settings. 3 key findings →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
Individuals with dementia live and frequently die in community settings. 1 key finding →
Design: prospective cohort Participants: 524 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Individuals aged 68+ years diagnosed with OAG have a decreased rate of AD or other dementia diagnosis compared to control patients without an OAG diagnosis. 3 key findings →
Design: cohort study Participants: 63,235 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Treatment with celecoxib or naproxen did not improve depressive symptoms over time compared with placebo. 5 key findings →
Design: longitudinal study Participants: 2,528 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
44 participants were included: 20 PSEN1 E280A mutation carriers and 24 non-carriers. 2 key findings →
Participants: 44 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →